Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer

J. Randolph Hecht, Jean Yves Douillard, Lee Schwartzberg, Axel Grothey, Scott Kopetz, Alan Rong, Kelly S. Oliner, Roger Sidhu

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

RAS family proteins (including KRAS and NRAS) play important roles in the epidermal growth factor receptor (EGFR) signaling pathway. Mutations in RAS genes (occurring at loci in exons 2, 3, and 4) often result in constitutive activation of RAS proteins and persistent downstream signaling. Mutations in KRAS exon 2 (codon 12/13) are an established predictor of lack of response to the anti-EGFR monoclonal antibodies cetuximab and panitumumab in patients with metastatic colorectal cancer (mCRC), and have been used routinely in clinical practice to identify patients unlikely to derive benefit from these therapies. However, a meaningful proportion of patients with mCRC have tumors bearing other mutations in RAS genes. Recent studies have demonstrated that evaluation of an extended panel of RAS mutations-including mutations in KRAS exon 2, 3, and 4 and NRAS exons 2, 3, and 4-can better define the patient population that is unlikely to benefit from anti-EGFR therapy, with concomitant improvements in outcomes in the more highly selected RAS wild-type group. This discovery has changed the practice of oncology and has the potential to spare patients from exposure to ineffective therapy. In the near future, it is important for the oncology community to validate extended RAS analysis assays and make certain that patients who are candidates for anti-EGFR therapy undergo appropriate testing and treatment.

Original languageEnglish (US)
Pages (from-to)653-659
Number of pages7
JournalCancer Treatment Reviews
Volume41
Issue number8
DOIs
StatePublished - Sep 1 2015

Fingerprint

Epidermal Growth Factor
Colorectal Neoplasms
Epidermal Growth Factor Receptor
Exons
Mutation
Therapeutics
Codon
Genes
Proteins
Monoclonal Antibodies
Population
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. / Hecht, J. Randolph; Douillard, Jean Yves; Schwartzberg, Lee; Grothey, Axel; Kopetz, Scott; Rong, Alan; Oliner, Kelly S.; Sidhu, Roger.

In: Cancer Treatment Reviews, Vol. 41, No. 8, 01.09.2015, p. 653-659.

Research output: Contribution to journalReview article

Hecht, J. Randolph ; Douillard, Jean Yves ; Schwartzberg, Lee ; Grothey, Axel ; Kopetz, Scott ; Rong, Alan ; Oliner, Kelly S. ; Sidhu, Roger. / Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. In: Cancer Treatment Reviews. 2015 ; Vol. 41, No. 8. pp. 653-659.
@article{ffe3ed4f34c94fabb853fafaa14b132d,
title = "Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer",
abstract = "RAS family proteins (including KRAS and NRAS) play important roles in the epidermal growth factor receptor (EGFR) signaling pathway. Mutations in RAS genes (occurring at loci in exons 2, 3, and 4) often result in constitutive activation of RAS proteins and persistent downstream signaling. Mutations in KRAS exon 2 (codon 12/13) are an established predictor of lack of response to the anti-EGFR monoclonal antibodies cetuximab and panitumumab in patients with metastatic colorectal cancer (mCRC), and have been used routinely in clinical practice to identify patients unlikely to derive benefit from these therapies. However, a meaningful proportion of patients with mCRC have tumors bearing other mutations in RAS genes. Recent studies have demonstrated that evaluation of an extended panel of RAS mutations-including mutations in KRAS exon 2, 3, and 4 and NRAS exons 2, 3, and 4-can better define the patient population that is unlikely to benefit from anti-EGFR therapy, with concomitant improvements in outcomes in the more highly selected RAS wild-type group. This discovery has changed the practice of oncology and has the potential to spare patients from exposure to ineffective therapy. In the near future, it is important for the oncology community to validate extended RAS analysis assays and make certain that patients who are candidates for anti-EGFR therapy undergo appropriate testing and treatment.",
author = "Hecht, {J. Randolph} and Douillard, {Jean Yves} and Lee Schwartzberg and Axel Grothey and Scott Kopetz and Alan Rong and Oliner, {Kelly S.} and Roger Sidhu",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.ctrv.2015.05.008",
language = "English (US)",
volume = "41",
pages = "653--659",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer

AU - Hecht, J. Randolph

AU - Douillard, Jean Yves

AU - Schwartzberg, Lee

AU - Grothey, Axel

AU - Kopetz, Scott

AU - Rong, Alan

AU - Oliner, Kelly S.

AU - Sidhu, Roger

PY - 2015/9/1

Y1 - 2015/9/1

N2 - RAS family proteins (including KRAS and NRAS) play important roles in the epidermal growth factor receptor (EGFR) signaling pathway. Mutations in RAS genes (occurring at loci in exons 2, 3, and 4) often result in constitutive activation of RAS proteins and persistent downstream signaling. Mutations in KRAS exon 2 (codon 12/13) are an established predictor of lack of response to the anti-EGFR monoclonal antibodies cetuximab and panitumumab in patients with metastatic colorectal cancer (mCRC), and have been used routinely in clinical practice to identify patients unlikely to derive benefit from these therapies. However, a meaningful proportion of patients with mCRC have tumors bearing other mutations in RAS genes. Recent studies have demonstrated that evaluation of an extended panel of RAS mutations-including mutations in KRAS exon 2, 3, and 4 and NRAS exons 2, 3, and 4-can better define the patient population that is unlikely to benefit from anti-EGFR therapy, with concomitant improvements in outcomes in the more highly selected RAS wild-type group. This discovery has changed the practice of oncology and has the potential to spare patients from exposure to ineffective therapy. In the near future, it is important for the oncology community to validate extended RAS analysis assays and make certain that patients who are candidates for anti-EGFR therapy undergo appropriate testing and treatment.

AB - RAS family proteins (including KRAS and NRAS) play important roles in the epidermal growth factor receptor (EGFR) signaling pathway. Mutations in RAS genes (occurring at loci in exons 2, 3, and 4) often result in constitutive activation of RAS proteins and persistent downstream signaling. Mutations in KRAS exon 2 (codon 12/13) are an established predictor of lack of response to the anti-EGFR monoclonal antibodies cetuximab and panitumumab in patients with metastatic colorectal cancer (mCRC), and have been used routinely in clinical practice to identify patients unlikely to derive benefit from these therapies. However, a meaningful proportion of patients with mCRC have tumors bearing other mutations in RAS genes. Recent studies have demonstrated that evaluation of an extended panel of RAS mutations-including mutations in KRAS exon 2, 3, and 4 and NRAS exons 2, 3, and 4-can better define the patient population that is unlikely to benefit from anti-EGFR therapy, with concomitant improvements in outcomes in the more highly selected RAS wild-type group. This discovery has changed the practice of oncology and has the potential to spare patients from exposure to ineffective therapy. In the near future, it is important for the oncology community to validate extended RAS analysis assays and make certain that patients who are candidates for anti-EGFR therapy undergo appropriate testing and treatment.

UR - http://www.scopus.com/inward/record.url?scp=84941025652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941025652&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2015.05.008

DO - 10.1016/j.ctrv.2015.05.008

M3 - Review article

VL - 41

SP - 653

EP - 659

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 8

ER -